Deals In Depth: January 2017
Executive Summary
Servier signed a $1.7 billion immuno-oncology deal with Pieris; Johnson & Johnson paid $30 billion to acquire Actelion and its key pulmonary arterial hypertension assets. Device fundraising was significantly boosted by Verily's $800 million investment from Temasek.
Exhibit 1
Top Alliances In January 2017
Strategic Transactions | Pharma Intelligence, 2017
Exhibit 2 Top Mergers & Acquisitions In January 2017
Strategic Transactions | Pharma Intelligence, 2017
Exhibit 3 Financings By Type ($m)
Strategic Transactions | Pharma Intelligence, 2017
Exhibit 4 Six-Month Snapshot Of Public And Private Financing
Strategic Transactions | Pharma Intelligence, 2017